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Following brain injury, S100B is released from damaged astrocytes but also yields repair mechanisms. We measured S100B in
the cerebrospinal ﬂuid (CSF) and serum (Cobas e411 electrochemiluminescence assay, Roche) longitudinally in a large cohort of
patients treated with a ventricular drainage following traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH). Statistical
analysis was performed with SPSS software applying the Mann-Whitney rank sum test or chi-test where appropriate. S100B in
CSF and serum was signiﬁcantly increased following TBI (n = 71) and SAH (n = 185) for at least one week following injury.
High S100B levels in CSF and serum were inconsistent associated with outcome. The passage of S100B from CSF to blood
(100
∗serumS100B/CSFS100B) was signiﬁcantly decreased although the albumin quotient suggested an “open” blood-CSF barrier.
Events possibly interfering with the BBB did not aﬀect the S100B passage (P = .591). In conclusion, we could not conﬁrm S100B
measurements to reliably predict outcome, and a compromised blood-CSF barrier did not aﬀect the passage of S100B from CSF
to serum.
1.Introduction
There is a desire for a reliable indicator to accurately deter-
mine the extent of brain injury and consequent prognosis.
The measurement of putative biochemical markers, such
as the S100B protein, has been proposed in this role. Fur-
thermore, such a biomarker would aid in identifying events
contributing to secondary brain damage and monitoring the
success of therapeutic interventions.
Over the past decade, numerous studies have reported
a positive correlation between S100B levels in blood or
cerebrospinal ﬂuid (CSF) and impaired neurological func-
tion following traumatic brain injury (TBI) [1], intrac-
erebral hemorrhage [2], stroke [3], perinatal brain dam-
age [4], septic encephalopathy [5], bacterial meningitis
[5], or even in major depression [6], and extracranial
injuries [7]. Furthermore, S100B levels have been used
to monitor therapeutic eﬀects such as the application of
hypertonic saline in TBI [8]o ro fn a l o x o n ei ne p i l e p s i a
[9]. However, considerable evidence indicates that S100B is
not only a biomarker of brain damage but also represents
ongoing neuroregeneration [10]. Moreover, contradictory
data interpretation exists with regard to the contribution of
an altered blood-brain barrier (BBB) to S100B serum levels
[11, 12].
Although in cell cultures the injury-induced S100B
release continues to increase up to 48 hours [13, 14],
in patients S100B serum levels have been reported to be
highest directly after the injury and become normalized
within 24 hours in a high percentage of cases, even in
those patients with a bad outcome [15]. The underlying
mechanism describing the passage of S100B from brain to
blood following acute brain injury has not yet been clariﬁed,
nor does an unequivocal data interpretation exist regarding
cerebral S100B levels and their correlation to serum S100B
levels.
Opposite to the BBB, the compartmental barrier within
the ventricles is not at the level of the blood vessels but2 Cardiovascular Psychiatry and Neurology
between the epithelial cells that form the inner CSF-facing
surface of the choroid plexus. Since the choroid plexus are
of mesodermal origin, their leaky capillaries are one of
the exceptions to the rule that almost all capillaries in the
central nervous system (CNS) form tight junctions between
their endothelial cells thereby establishing the BBB. CSF is
directly secreted by the choroid plexus into the ventricles
constituting a blood ultraﬁltrate and is also derived from the
extracellularﬂuid(ECF).TheECFcommunicatesreasonably
freely with the ventricular CSF through normal nonbarrier
spaces between ependymal cells [16]. CSF production is
measured by dilution studies, and a total volume of 130ml
CSF in men is renewed every 5–7 hours. The classic view of
CSF removal is to pass through the arachnoid villi into the
venous sinuses by bulk ﬂow [17], but alternatively CSF may
pass into the blood vessels driven by a mixing or pulsatile
ﬂow [18].
Although the functional assessment of the dynamics of
p r o t e i np a s s a g ef r o mb l o o dt ob r a i no rvice versa in CNS
disorders is of general interest, in patients the means of
quantiﬁcation are limited. Since blood and CSF are readily
accessible, calculating respective ratios is reasonable. The
albuminCSF/albuminserum quotient(QA)hasbeenestablished
as the “golden standard” for the assessment of blood-CSF
barrier dysfunction [19, 20] although it is occasionally
mistaken to measure BBB permeability. The 66 KD protein
albumin is synthesized peripherally, is not catabolised within
the CNS, and does not readily diﬀuse across an intact BBB.
In adults, normal values are deﬁned as a QA ≤ 0.007,
a n dad a m a g e do ro p e nb l o o d - C S Fb a r r i e ri sd e ﬁ n e da s
mild (QA = 0.007–0.01), moderate (QA = 0.01–0.02), and
severe (QA ≥ 0.02), respectively [21]. Applying the QA,i t
is important to note that the ratio has been established in
lumbarCSF.Extensivestudiesonthedynamicsofblood-and
brain-derived proteins across the blood-CSF barrier support
the view that blood-CSF barrier dysfunction is a biophysical
concept of increased molecular ﬂux with decreasing CSF
ﬂow rate rather than a morphological “leakage” model
[22].
Thus, interpreting the serum and CSF levels of the
22kD dimeric neurotrophic protein S100B following acute
brain damage is a dual challenge. Firstly, reasonable evi-
dence exists that S100B is not only passively released by
damaged astrocytes but also actively secreted and acts in
a positive paracrine manner to foster neuronal repair or
regeneration. Secondly, protein reabsorption accompanying
CSF turnover emerges as a possibility. Facing the limi-
tations of in vitro and in vivo experimental models, we
conﬁned ourselves to data collection in the clinical setting
of acute brain injury. In particular, the purpose of the
present study was (i) to examine the temporal proﬁle
of S100B release into CSF and blood in a large cohort
of patients following TBI and subarachnoid hemorrhage
(SAH) longitudinally, (ii) to calculate the ratio of S100B
in the CSF/serum in order to estimate the passage from
CSF to blood, and (iii) to correlate the respective S100B
levels with the neurological function and recovery as well
as with speciﬁc events known to interfere with the BBB
integrity.
2. Methods
2.1. Subjects. The study was approved by the Ethics Com-
mittee of our hospital and was conducted in compliance
with the Declaration of Helsinki. Informed consent was
obtained from the next of kin of the patient. Patients were
included unless one of the following exclusion criteria was
present: age <18 years; pregnancy or nursing state; primary
central nervous disorders (e.g., meningitis, neoplasm, or
known epilepsy); expected to die within the ﬁrst 48 hours;
melanoma; severe burns, orthopaedic surgery, or cardiac
bypass surgery. Patients were enrolled into two groups, one
presenting with isolated TBI requiring ventriculostomy and
catheter placement (n = 71) and the other presenting with
SAH (n = 185). Normal values of S100B in serum and CSF
in healthy controls had been established in the past in [12].
Since the normal values in this study were established in the
lumbar CSF of control patients, we applied a 3.5 correction
factor according to the CSF ﬂow rate model of Reiber [22].
In the study patients, ventriculostomy catheters were
placed as part of the clinical care within 12 hours of
admission. Ventriculostomy catheters are typically placed to
monitor intracerebral pressure in patients with severe TBI
(Glasgow Coma Scale [GCS] score ≤8) and an intracranial
injury on computed tomography (CT) scan. However, these
catheters are also placed in those with severe TBI and a
normal CT if two or more of the following factors are
present: age >40 years, unilateral/bilateral motor posturing,
and systolic blood pressure <90mmHg [23]. In some
cases, subjects with initial GCS scores above 8 received
ventriculostomy catheters because of subsequent clinical
deterioration and were included in the study. Subjects were
eligible for inclusion as a SAH subject if the diagnosis was
conﬁrmed by CT or an abnormal lumbar puncture.
Extracranial and brain injury were documented by CT,
neurological function by the GCS and Glasgow outcome
Score (GOS), as well as intensive care scores (APACHE
and/or SAPS). All events potentially interfering with S100B
passage were recorded: hypotonia (mean blood pressure <
65mmHg), hypoxia (SpO2 < 90%), hyperthermia (>38◦C),
increased intracranial pressure (ICP > 20mmHg), treat-
ment with mannitol, increased cerebral blood ﬂow velocity
(>80cm/s),andtreatmentmodalitiesasaneurysmsurgeryor
coiling, change of ventricular drainage, shunt implantation,
or tracheotomy.
2.2. Sample Collection and Processing. In TBI and SAH sub-
jects, we collected blood and CSF samples daily at 8 AM for
up to 4 weeks postinjury. For all blood draws, 4 ml of venous
or arterial blood were drawn into serum separator tubes and
centrifugedat3000rpmfor10minutesatroomtemperature.
The cellular components were discarded and the serum
stored at −80
◦C until used for assays. CSF was collected
at the time of blood draws. For each CSF sample, 5–10ml
were collected into a 15 ml polypropylene tube, immediately
placed on ice, and centrifuged at 3000 rpm for 10minutes at
room temperature. The cellular components were discarded
and the remaining sample stored at −80
◦C until used for
assays. Serum S100B concentrations were measured withCardiovascular Psychiatry and Neurology 3
the Cobas e411 S100 electrochemiluminescence assay, Roche
Diagnostics. S100B concentrations in the serum samples
were determined using the standard curve generated from
the absorbance of the standards. The lower detection limit
of this assay is 0.005μg/l, the upper limit 39μg/l. In order
to quantify the S100B passage from CSF into blood, we
calculated the S100B ratio in serum originating from CSF
(= 100∗serumS100B/CSFS100B).
Albumin was analysed by immunochemical nephelome-
try,BNProspec,SiemensDiagnostics,asdescribedelsewhere
[24]. The standard calibration curve for CSF measurements
was also applied for serum measurements following an
instrumented dilution either by x400 or x2000. Analysis
of the blood-CSF barrier function was determined using
the CSFalbumin/serumalbumin ratio (QA). Daily albumin values
weremeasuredinCSFandserum,andtheQA wascalculated.
Since our albumin analyses were performed in ventricular
CSF, a correction factor for a ventricular to lumbar CSF
gradient of 1:2.5 was applied, and a relevant disturbance
of the blood-CSF barrier function was assumed if the QA
exceeded 0.0028 [21, 22].
2.3. Statistical Analysis. A l lv a l u e sa r eg i v e na sm e a n± SEM.
The statistical analysis was performed using SPSS (SPSS
Inc., Chicago, IL) and R (open source software). Group
comparisons, such as TBI versus SAH, or good (GOS 4 +
5), moderate (GOS 3), and worse (GOS 1 + 2) outcome
were made applying the Mann-Whitney rank sum test since
no normal distribution was present. Correlation analysis
between S100B values and the QA was performed using
the nonparametric Kendall’s tau b Pearson correlation test.
The chi-test was used to compare the incidence of events
associated with an increase or decrease of S100B levels.
Signiﬁcance was deﬁned as P<. 05.
3. Results
We included 71 patients admitted for TBI and 185 patients
following SAH. The normal S100B values had been estab-
lished in control patients undergoing pituitary surgery
treated with a lumbar drainage at 0.07μg/li ns e r u ma n da t
2.87μg/l in CSF applying a 3.5 correction factor to normalize
for the negative ventricular-lumbar CSF gradient of brain-
derived proteins. S100B in CSF was signiﬁcantly increased
up to day 7 following TBI (64.98 ± 272.39μg/l,P = .024)
and SAH (146.90 ± 1374.86μg/l,P = .009) and in serum up
to day 8 following TBI (0.16 ± 0.30μg/l,P = .032) and up
to day 14 following SAH (0.33 ± 1.12μg/l,P = .016). The
time course of the S100B concentration in serum and CSF in
185 SAH patients and 71 TBI patients is displayed in Figures
1(a) and 1(b). Statistical comparison between the diﬀerent
types of acute brain injury by the Whitney-Mann rank sum
test revealed that S100B in CSF and serum was signiﬁcantly
higher following TBI than SAH for the ﬁrst 5 days (P<. 05).
3.1. S100B Serum/CSF Ratio and the Blood-CSF Barrier. In
order to quantify the S100B passage from CSF into blood,
we compared the ratio serumS100B/CSFS100B. In the control
patients, S100B in serum comprised around 2.8% of the
respective CSF concentration, applying a 3.5 correction
factor for the negative ventricular to lumbar CSF gradient.
The S100B ratio in SAH and TBI patients was signiﬁcantly
reduced for the ﬁrst 4 days (P<. 05). In accordance
to the literature, we quantiﬁed the ratio QA, respectively,
CSFAlbumin/serumAlbumin reﬂecting the passage of albumin
from blood to the brain. The QA was signiﬁcantly increased
over the investigation period (day 1:0.015±0.012, day
10:0.016±0.013)ascomparedtonormalvalues(QA[normal
for ventricular CSF] ≤ 0.0028, P<. 05). There was no
correlation between the S100B ratio and the QA (day 1: r =
0.233, P = .615, day 7: r = 0.110,P = .860).
3.2. Prediction of Outcome. Within the groups, there was
no consistent correlation between S100B concentrations in
either serum or CSF and neurological function as assessed
by GCS. The statistical analysis of outcome prediction and
S100B levels revealed inconsistent ﬁndings, especially in TBI
patients. SAH patients with worse outcome (GOS 1 + 2) had
signiﬁcantly higher S100B serum levels on day 2 (P = .042),
day 3 (P = .042), and day 4 (P = .031) as compared to
moderate outcome (GOS 3) and on day 5 (P = .006), day 7
(P = .004), day 11 (P = .012), day 12 (P = .008), day 13
(P = .003), day 14 (P = .003), day 15 (P = .032), and day
17 (P = .036) as compared to good outcome (GOS 4 + 5).
SAH patients with worse outcome had signiﬁcantly higher
S100B CSF levels on day 1 (P = .011), day 2 (P = .010),
and day 3 (P = .010) as compared to moderate outcome and
on day 5 (P = .011), day 7 (P = .021), day 10 (P = .003),
day 12 (P = .012), and day 13 (P = .028) as compared
to good outcome. SAH patients with worse outcome had a
signiﬁcantly impaired S100B CSF/serum passage on day 3
(P = .026) as compared to moderate outcome and on day
10 (P = .039) as compared to good outcome. TBI patients
with worse outcome had signiﬁcantly higher S100B serum
levels on day 2 (P = .019) as compared to good outcome.
TBI patients with worse outcome had signiﬁcantly lower
S100B CSF levels on day 3 (P = .016) as compared to
moderate outcome. TBI patients with worse outcome had
a signiﬁcantly improved S100B CSF/serum passage on day 3
(P = .016) as compared to moderate outcome.
3.3.EventsAﬀectingS100BLevels. In30patients,weanalyzed
events possibly interfering with the BBB in detail (Figure 2).
Neither hypotonia (mean blood pressure < 65mmHg) nor
hypoxia (SpO2 < 90%), hyperthermia (>38◦C), increased
intracranial pressure (ICP > 20mmHg), treatment with
mannitol, increased cerebral blood ﬂow velocity (>80cm/s),
or treatment modalities as aneurysm surgery or coiling,
change of ventricular drainage, shunt implantation or tra-
cheotomydidaﬀectthepassageofS100Boralbuminthrough
the blood-CSF barrier (P = .591). The incidence of events is
displayed in Figure 3.
3.4. Contribution of Extracerebral S100B Sources. In TBI
patients, the contribution of extracerebral sources to S100B4 Cardiovascular Psychiatry and Neurology
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Figure 1: Mean S100B levels in CSF (a) and serum (b) following subarachnoid hemorrhage (SAH) or traumatic brain injury (TBI). The
values are given as mean ±SEM.
levels was assessed. One patient suﬀered from a femur frac-
ture contributing to excessively elevated S100B serum levels
on admission (1.22μg/l). However, S100B was cleared from
serum on the following day (0.25μg/l), and CSF levels on
admission remained below mean values (36.98μg/l), and for
the total investigation period. In two other patients with a
fracture of the clavicle, S100B serum levels were not aﬀected.
Furthermore, S100B is expressed in relevant concentrations
in adipose tissue [25], and S100B serum levels were reported
to correlate with the BMI and speculated to be closely linked
to an altered energy metabolism in diabetic patients [26]. In
our study, obesity did not signiﬁcantly aﬀect S100B serum
levels while in diabetic patients, S100B serum levels were
signiﬁcantly higher than in nondiabetic ones (P = .013).
4. Discussion
To the best of our knowledge, this is the ﬁrst study to
investigate concurrentconcentrationsofS100B inserumand
CSF in more than 250 patients following acute brain injury
longitudinally for up to 4 weeks. As it has been iterated
by a plethora of authors, we found some correlation of
high S100B levels and worse outcome, but far from any
prerequisite of unequivocal outcome prediction. Opposite to
common reasoning, in our study the passage of S100B from
CSF to serum was impaired following acute brain injury.
We could not conﬁrm any contribution of a compromised
blood-CSF barrier to S100B serum levels.
4.1. Release of S100B into CSF. Neither the role of the glial
protein S100B in the acutely injured brain nor the release
into the ECF and the subsequent passage to the CSF and
blood has been established. From in vitro injury, we learned
that S100B is released into the culture medium [13, 14]. The
ECFcommunicateswiththeCSFthroughnormalnonbarrier
spaces [16], presumably allowing S100B to pass freely from
the ECF to the CSF. Thus, it is reasonable to assume that
S100B CSF concentration measured following human brain
injury reﬂects the S100B release into the ECF. The injury-
induced S100B release in cell cultures displayed an upward
slope over the investigation period [14] demonstrating an
active stimulated release contributing to the total S100B
concentration measured. In vivo data suggest a S100B
release due to learning and memory processes [27, 28]. In
patients, electroshock therapy did not aﬀect S100B serum
levels [29], but acute psychosis resulted in an increased
concentration of S100B in CSF and serum [30]. The long-
lasting increased S100B levels in CSF found in our patients
followingSAHorTBIareunlikelytoresultpurelyfrombrain
injury. Furthermore, we were unable to verify any consistent
correlation of S100B CSF levels and injury severity or
outcome. However, since a strong S100B immunopositivity
of the ependymal and choroid plexus epithelia has been
observed although the functional consequences have not
been elucidated yet, we cannot exclude a contribution from
these cells to the S100B CSF concentration [31]. A limitation
of our study is comparing the ventricular CSF measurements
from our patients with lumbar CSF measurements from
controls subjects of a previous study. To eliminate any
interference of ventricular-lumbar protein gradients, we
applied an estimated “correction factor” of 3.5 for S100B and
of 0.4 for albumin [22]. Taken together, the literature and
our ﬁndings imply an active stimulated S100B release into
CSF reﬂecting neuronal-glial activation, synaptic plasticity,
or neuroregeneration rather than to result from injured cells.
4.2. Brain-CSF-Blood Barrier. Increased S100B concentra-
tions in the blood have been attributed to the passage
through an impaired BBB following brain injury [26],
whenever an extracerebral origin of S100B was excluded [26,
32, 33]. However, contradictory data interpretation exists
with regard to the contribution of an altered BBB to S100B
serum levels [12].
The BBB prevents diﬀusion of most water-soluble
molecules over 500 Da. Although the albuminCSF/albu-
minserum quotient (QA) has originally been described forCardiovascular Psychiatry and Neurology 5
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Figure 3: Events potentially interfering with the blood-brain
barrier (BBB) and the eﬀect on the S100B concentration in CSF and
serum following subarachnoid hemorrhage (SAH) or traumatic
brain injury (TBI). The chi-test did not reveal any impact of events
on S100B levels.
the blood-CSF barrier dysfunction [19, 20], several authors
calculated indices using the QA as a measure of “BBB”
permeability following TBI, such for the intercellular adhe-
sion molecule-1 (ICAM-1) [34], for the antiinﬂammatory
transforming growth factor-beta (TGF-beta) [35], or for
the complement-derived soluble membrane attack com-
plex (sC5b-9) [36], and they reported the respective CSF
levels paralleling the “BBB” function as assessed by the
QA. However, other authors could not conﬁrm such a
correlation, for example, assessing the cerebral produc-
tion of interleukin (IL)-10 [37] or IL-6, IL-8 and IL-10
[38].
The lessons we learned from these controversies are
twofold. First, any ratio CSFSUBSTANCE/serumSUBSTANCE does
reﬂect the passage of the respective protein through the
blood-CSF barrier that is clearly to distinguish from the
BBB and is a measure of an altered CSF ﬂow [22]. Second,
the albuminCSF/albuminserum quotient QA allows inference
on proteins around 66KD, while the dimeric 22KD protein
S100B may comply diﬀerent dynamics.
4.3. Passage of S100B from Brain to Blood. Following a
preliminary study including few patients and assessing the
release and wash-out pattern of S100B in serum and CSF,
the importance to know the underlying pathology and
timing in interpreting S100B levels has been highlighted
[39]. We analyzed the impact of several pathophysiolog-
ical dysregulations like hypotonia, hypoxia, hyperthermia,
increased intracranial pressure, vasospasm, and craniotomy
known to aﬀect the BBB. Furthermore, the BBB has been
reported to be opened osmotically [40]. In our study, those
events likely to interfere with the BBB and treatment with
mannitol did not aﬀect the passage of S100B from the CSF to
blood.
Opposite to the BBB, the compartmental barriers
between the CSF and blood are leaky capillaries of the
choroid plexus allowing protein secretion into the CSF. Little
is known whether this secretion is unidirectional or may
allow the reabsorption of proteins from the CSF into blood.
Furthermore, the relevance of the blood-CSF barrier in
acute brain damage remains unclear. Ultrastructural exam-
inations of the choroidal epithelial cells forming the CSF-
blood barrier following experimental injury demonstrate
pronounced changes lasting up to 4 weeks postinjury [41].
Accordingly, the reduced ratio of S100B serum/CSF found in
our patients may result from damaged choroidal epithelial
cells hampering with the S100B passage from CSF to blood
[31]. However, considerable evidence indicates that S100B
is not only a biomarker of brain damage but also represents
ongoing repair or neuroregeneration [10]. Thus, the reduced
passage of the neurotrophic protein S00B from CSF to
blood may result from an increased demand in injured
tissue.
5. Conclusion
Although there is a reasonable desire for a reliable indicator
to accurately determine the extent of brain injury and to
monitor therapeutic interventions, advocating S100B in this
role remains problematic. While a substantial body of evi-
dence demonstrates an association between S100B and bad
outcome after brain injury, it is important to be aware that
proof of an association is not proof of causation in science.
In the present large cohort of patients, the concurrent
measurement of S100B in serum and CSF, we found some
association of high S100B levels and worse outcome, but far
from any prerequisite of unequivocal outcome prediction.
Opposite to common reasoning, we found the passage
of S100B from CSF to serum impaired following acute
brain injury. We could not conﬁrm any contribution of a
compromised BBB or blood-CSF barrier to S100B serum
levels.Cardiovascular Psychiatry and Neurology 7
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